BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down – Here’s What Happened

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares gapped down before the market opened on Tuesday . The stock had previously closed at $7.46, but opened at $7.23. BioCryst Pharmaceuticals shares last traded at $7.43, with a volume of 67,628 shares.

Wall Street Analyst Weigh In

Several analysts have recently commented on BCRX shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Barclays raised their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.60.

BioCryst Pharmaceuticals Trading Down 2.4 %

The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -11.98 and a beta of 1.79. The business has a 50 day simple moving average of $7.62 and a 200-day simple moving average of $7.42.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same quarter in the prior year, the firm earned ($0.19) EPS. The company’s revenue for the quarter was up 35.1% compared to the same quarter last year. Research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently modified their holdings of the business. CWM LLC boosted its stake in BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,772 shares during the last quarter. Signaturefd LLC lifted its position in shares of BioCryst Pharmaceuticals by 560.5% during the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares in the last quarter. nVerses Capital LLC bought a new stake in BioCryst Pharmaceuticals in the second quarter valued at about $63,000. Finally, DRW Securities LLC acquired a new stake in BioCryst Pharmaceuticals during the second quarter valued at approximately $74,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.